AbbVie Inc.
ABBVBusiness Model
ticker: ABBV step: 01 generated: 2026-05-11 source: quick-research
AbbVie Inc. (ABBV) — Business Overview
Business Description
AbbVie is a global research-based biopharmaceutical company spun off from Abbott Laboratories in 2013. Its business is anchored by immunology (Skyrizi + Rinvoq + Humira), with sizable franchises in neuroscience, oncology, aesthetics (Allergan's Botox + Juvederm), and eye care. After successfully navigating the largest patent cliff in pharma history (Humira, peak $21.2B sales in 2022), AbbVie's combined Skyrizi + Rinvoq sales exceeded $25B in 2025 and are tracking to >$31B by 2027 — already surpassing peak Humira.
Revenue Model
- Immunology (~45% of revenue): Skyrizi (IL-23), Rinvoq (JAK), residual Humira (TNF) — fast-growing replacements offsetting Humira biosimilar erosion
- Oncology (~10%): Imbruvica (BTK, partnered with J&J), Venclexta, Epkinly, Elahere
- Neuroscience (~14%): Vraylar, Botox Therapeutic, Ubrelvy, Qulipta — growing 17%+ annually
- Aesthetics (~9%): Botox Cosmetic, Juvederm, CoolSculpting (acquired via Allergan 2020)
- Eye Care (~6%): Restasis, Xen, Vuity (presbyopia)
- Other (~16%): Mavyret (HCV), Creon, Hytrin
Products & Services
- Skyrizi (risankizumab): IL-23 inhibitor for psoriasis, psoriatic arthritis, Crohn's, ulcerative colitis — $17.6B in 2025 ($21.5B 2026E)
- Rinvoq (upadacitinib): JAK1 inhibitor for RA, psoriatic arthritis, atopic dermatitis, IBD, vitiligo (filed) — $8.3B in 2025 ($10.1B 2026E)
- Humira (adalimumab): Legacy TNF inhibitor, now ~$2.9B/year and shrinking ~40% annually post-LOE
- Botox / Juvederm: Aesthetics franchise from $63B Allergan acquisition (2020)
- Vraylar: Atypical antipsychotic for bipolar, depression
- Vylept: New Parkinson's drug (FDA approved 2026)
- Pipeline: Tirvapadone (Parkinson's, Phase 3), Entantamig (multiple myeloma, Phase 3), Crohn's combo platform
Customer Base & Go-to-Market
- Patients: Millions globally, often with chronic disease (autoimmune, oncology)
- Prescribers: Specialist physicians (rheumatology, dermatology, gastroenterology, neurology, oncology)
- Payers: US PBMs/insurers, ex-US single-payer systems negotiate aggressively
- Aesthetics channel: Direct to dermatologists and plastic surgeons; consumer awareness via DTC marketing
- Geographic mix: ~75% US revenue, ~25% International
Competitive Position
AbbVie has the most successful biopharma post-LOE transition on record — Skyrizi and Rinvoq combined have already surpassed peak Humira. Moats include (1) strong specialty sales force relationships in immunology, (2) scientifically differentiated mechanisms (IL-23 + JAK selective JAK1), (3) Allergan aesthetics distribution franchise, and (4) capital allocation discipline using free cash flow for tuck-in M&A (ImmunoGen, Cerevel) to refresh pipeline. Competes with J&J (Stelara, Tremfya), Eli Lilly (Olumiant, Omvoh), Bristol-Myers (Sotyktu), Pfizer (Xeljanz), Roche (Vabysmo) across therapy areas.
Key Facts
- Founded: 2013 (spin off from Abbott Labs)
- Headquarters: North Chicago, IL
- Employees: ~55,000
- Exchange: NYSE
- Sector / Industry: Health Care / Pharmaceuticals
- Market Cap: ~$365B (May 2026)
- CEO: Rob Michael (succeeded Richard Gonzalez 2024)
- Dividend: ~$6.59 annual; 52+ consecutive years (counting Abbott history) — Dividend King via predecessor lineage
Financial Snapshot
ticker: ABBV step: 04 generated: 2026-05-11 source: quick-research
AbbVie Inc. (ABBV) — Financial Snapshot
Income Statement Summary
| Metric | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $54.3B | $56.3B | $61.2B | +8.6% |
| Adj. Gross Margin | 84% | 84% | 84% | flat |
| Adj. Operating Margin | 47% | 46% | 47% | +1pp |
| Adj. Net Income | $21.5B | $20.5B | $22.4B | +9% |
| Adj. EPS (diluted) | $11.11 | $10.61 | $12.20 | +15% |
Product Sales (FY2025 vs FY2024)
| Drug | FY2024 | FY2025 | YoY |
|---|---|---|---|
| Skyrizi | $11.7B | $17.6B | +50% |
| Rinvoq | $6.0B | $8.3B | +39% |
| Humira | $9.0B | $5.5B | -39% |
| Skyrizi + Rinvoq combined | $17.7B | $25.9B | +46% |
| Total Immunology | ~$27B | ~$32B | +18% |
| Imbruvica | $3.1B | $2.9B | -7% |
| Vraylar (neuroscience) | $3.0B | $3.5B | +17% |
| Botox Cosmetic | $2.7B | $2.8B | +4% |
Q1 2026 Highlights
| Metric | Q1 2026 | YoY |
|---|---|---|
| Total Revenue | ~$13.5B | +12.4% |
| Skyrizi | $4.48B | +30.9% |
| Rinvoq | ~$2.4B | +20% |
| Humira | $688M | -39% |
Cash Flow & Balance Sheet (FY2025)
| Metric | Value |
|---|---|
| Operating Cash Flow | ~$22B |
| Capital Expenditures | ~($1.0B) |
| Free Cash Flow | ~$21B |
| Cash & Equivalents | ~$5B |
| Total Debt | ~$67B (post Allergan/ImmunoGen/Cerevel) |
| Net Debt / EBITDA | ~2.0x (declining) |
Key Ratios (approximate, May 2026)
- P/E (forward): ~14x | EV/EBITDA: ~13x | Dividend Yield: ~3.2%
- ROIC: ~14% | FCF/Net Income conversion: ~95%
Growth Profile
2025 was the inflection year: total revenue +8.6%, with Skyrizi (+50%) and Rinvoq (+39%) more than offsetting Humira (-39%). Management guides 2026 revenue to $67B (+9.5%) and EPS to $14.37-14.57. Combined Skyrizi+Rinvoq guidance raised to >$31B by 2027 (vs. prior $27B), implying 19% organic CAGR despite Humira running off to ~$2B/year. Aesthetics segment softening (consumer discretionary headwind) but immunology + neuroscience more than offsetting.
Forward Estimates
- 2026E Revenue: $67B (mgmt guide; +9.5%)
- 2026E Adj EPS: $14.37-14.57 (mgmt guide)
- 2027E Revenue: ~$73B (consensus)
- 2027E Adj EPS: ~$16
- Skyrizi 2027 target: >$20B (raised from $17B)
- Rinvoq 2027 target: >$11B (raised from $10B)
Capital Return
- Dividend $6.59/share annual = ~$11.5B paid
- 52+ years of consecutive dividend growth (counting Abbott predecessor)
- Modest buybacks (~$2B/year) given priority on debt paydown post-Allergan
- Total return: ~3.2% dividend yield + buybacks + 9%+ FCF growth
Recent Catalysts
ticker: ABBV step: 12 generated: 2026-05-11 source: quick-research
AbbVie Inc. (ABBV) — Investment Catalysts & Risks
Bull Case Drivers
Skyrizi + Rinvoq exceeding peak Humira already — Combined 2025 sales of $25.9B already exceed Humira's $21.2B 2022 peak. Q1 2026: Skyrizi +30.9% to $4.48B, Rinvoq +20%. Mgmt raised 2027 combined target to >$31B (from prior $27B). The IL-23 + JAK-selective combo is winning indication after indication — psoriasis, PsA, Crohn's, UC, atopic dermatitis, vitiligo (filed). This proves the post-Humira transition is more successful than original guidance suggested.
2026 inflection: 9.5% revenue growth, EPS $14.37-14.57 — Management's 2026 guidance demonstrates the company has decisively cleared the Humira biosimilar headwind. With Humira now <$3B/year and shrinking ~40% annually (stable run-rate $1-2B by 2027), every dollar of Skyrizi/Rinvoq growth drops to revenue. Operating leverage from immunology growth + cost discipline pushes Adj OM toward 48-49%.
Neuroscience as the next growth pillar — Vraylar (+17%) is a $3.5B drug growing as a leading bipolar/depression treatment. Cerevel acquisition added tirvapadone (Parkinson's, Phase 3) and emraclidine. Vylept (FDA approved 2026) adds another Parkinson's asset. Phase 3 success for tirvapadone could add $2B+ annually.
3.2% dividend yield + 52-year track record — AbbVie inherits the Abbott dividend lineage; combined the family has paid an increasing dividend for 52+ consecutive years. The dividend is well covered with FCF ($21B FCF vs $11.5B dividend). Combined with 14x forward P/E, this is a "GARP + yield" stock in a sector facing political headline risk.
Bear Case Risks
Humira erosion accelerating + Imbruvica IRA pricing — Humira -39% YoY in Q1 2026 to $688M with continued biosimilar share losses. Imbruvica (J&J-partnered) faces IRA Medicare price negotiations — sales guided to $2.2B in 2026 (-23%). Combined Humira + Imbruvica headwind is ~$1.5B/year drag on growth.
Skyrizi/Rinvoq LOE eventually — Skyrizi US LOE ~2032; Rinvoq US LOE ~2034. While distant, biopharma multiples typically compress 4-5 years pre-LOE. The current bull thesis assumes pipeline (Cerevel/ImmunoGen acquisitions, Crohn's combo, AbbVie internal R&D) successfully covers a second cliff. Failure to land another 3-4 blockbusters by 2028 risks repeating the patent cliff cycle.
Aesthetics weakness — Botox Cosmetic and Juvederm growth slowing (+4% in 2024) as discretionary consumer spending softens and GLP-1 weight-loss users reportedly need less facial filler. Q4 2025 commentary highlighted aesthetics softness; this previously high-margin segment provides less offset to other categories.
Debt + M&A discipline test — $67B total debt post-Allergan/Cerevel/ImmunoGen is large. Management has prioritized deleveraging but the pace depends on FCF stability. If immunology pricing pressure increases (IRA Part D negotiations, EU price referrals), the deleveraging pace slows, constraining further pipeline-refresh M&A.
Upcoming Events
- Q2 2026 earnings (late July) — Skyrizi/Rinvoq trajectory; Humira run-rate visibility
- Q3 2026 earnings (October) — Vitiligo Rinvoq approval / launch trajectory
- Tirvapadone Phase 3 readout — Late 2026 / Early 2027 — Parkinson's data could de-risk pipeline
- Crohn's combo data — Skyrizi + Rinvoq combo for severe IBD — pivotal data through 2026-27
- Entantamig (multiple myeloma) Phase 3 — Potential 2026-27 readout
Analyst Sentiment
Sell-side consensus is Buy / Strong Buy with average price targets in the $230-250 range vs. recent ~$203 trading levels (~13-23% upside). Bulls cite the proven post-Humira transition, 9.5% guided revenue growth, 14x P/E, and 3.2% dividend. Bears focus on the eventual Skyrizi/Rinvoq LOE, Imbruvica IRA decline, and aesthetics weakness. Net consensus is positive but multiple compression at LOE remains a long-term overhang.
Research Date
Generated: 2026-05-11
Full Research Available
This primer covers steps 1–3 of 21. The full deep dive includes moat analysis, DCF valuation, bull/bear scenarios, management quality, earnings transcript analysis, competitive positioning, returns on capital, institutional/insider activity, and an investment memo.